BWXT already trades at a premium to many defense peers, so the case is not a moonshot
rerating. The opportunity is steadier: defense nuclear
backlog stays durable, commercial nuclear content widens after
PCG, and BWXT gets more chances to sell qualified capacity into an undersupplied market. If management converts scarce assets into better contract quality and higher commercial mix, the stock can compound well even without a reactor supercycle.